Retraction

Worsening of Pre-Existing Valvulopathy With A New Obesity Drug Lorcaserin, A Selective 5-Hydroxytryptamine 2C Receptor Agonist: A Meta-Analysis of Randomized Controlled Trials

Paper Information

Record ID:
17125
Publication Date:
March 07, 2013
Retraction Date:
November 04, 2013 (12.0 years years ago)
Article Type:
Publisher:
Elsevier
Open Access:
Yes
PubMed ID:
Not indexed in PubMed
Retraction PubMed ID:
Not indexed in PubMed

Retraction Details

Citations (2)

2
Total Citations
1
Post-Retraction
(50.0%)
0
Pre-Retraction
0
Same Day
Post-Retraction Citation Analysis
0 Within 30 days
1 Within 1 year
0 After 2+ years
275 Days since retraction (latest)
Paper citing Worsening of Pre-Existing Valvulopathy With A New ...
Unknown Authors
Unknown Journal
Published: Unknown
Paper citing Worsening of Pre-Existing Valvulopathy With A New ...
Unknown Authors
Unknown Journal
Published: Aug 2014
275 days after retraction
Quick Stats
Total Citations: 2
Years Since Retraction: 12.0 years
Open Access: Yes
Last Checked: Never
Related Papers
Mapping the Future of Myocardial Ischemia Testing With Card…
Journal of the American College of Cardiology (JACC) • 3 citations
Gadolinium-Free Cardiac MR Stress T1-Mapping to Distinguish…
Journal of the American College of Cardiology (JACC) • 71 citations
Diagnosis of Microvascular Angina Using Cardiac Magnetic Re…
Journal of the American College of Cardiology (JACC) • 109 citations
Cardio-Oncology: Stronger Together
Journal of the American College of Cardiology (JACC) • 1 citations
Prognostic Value of Blood Pressure Modeleling in Women; Rec…
Journal of the American College of Cardiology (JACC) • 0 citations